ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MM-141 Trial Does Not Meet Primary, Secondary Endpoints
americanpharmaceuticalreview
June 27, 2018Merrimack announced top-line results from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer and high serum levels o
Pharma Sources Insight January 2025
